Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections

A. Kumar, D. L. Murray, C. B. Hanna, T. G. Kreindler, K. D. Jacobson, J. M. Bundy, K. Waxman, E. F. Finnerty, D. W. Folan, W. R. Drucker, J. G. Kane, M. Durnell, A. DiMattia, C. D. Hill

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In two prospective, randomized multicenter double-blind studies with a dosage of either 250 mg given four times a day (study A) or 500 mg given two times a day (study B), the comparative efficacy and safety of cephalexin hydrochloride (LY061188; Keftab) and cephalexin monohydrate (Keflex) for treatment of skin and soft tissue infections were determined. In study A, 97 patients received cephalexin hydrochloride and 101 patients received cephalexin monohydrate. In study B, 75 patients received cephalexin hydrochloride and 70 patients received cephalexin monohydrate. Diagnoses included abscesses, cellulitis, would infections, and infected dermatitis, and were comparable in the different treatment groups. Pathogens were isolated from 82% of patients enrolled; the majority of isolates were of Staphylococcus aureus, Streptococcus pyogenes, other staphylococcal species, and a few gram-negative bacteria. In study A, 68 of 71 (95.7%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 73 of 81 (90%) patients who received cephalexin monohydrate also responded satisfactorily. In study B, 56 of 58 (96.5%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 47 of 50 (94%) patients who received cephalexin monohydrate also responded satisfactorily. An adverse clinical event leading to discontinuation of the treatment drug developed in 17 of 343 (4.95%) patients in both studies. No differences were noted between the two drugs. Skin eruptions, pruritis, and mild gastrointestinal symptoms were the common adverse effects. These data suggest that cephalexin hydrochloride, a new formulation of cephalexin, is a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in a dosage of either 250 mg four times a day or 500 mg twice a day.

Original languageEnglish (US)
Pages (from-to)882-885
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume32
Issue number6
DOIs
StatePublished - Jan 1 1988

Fingerprint

Cephalexin
Soft Tissue Infections
Skin
Therapeutics
Cellulitis
Streptococcus pyogenes
Dermatitis
Pruritus
Anti-Infective Agents
Infection
Gram-Negative Bacteria
Double-Blind Method
Pharmaceutical Preparations
Abscess
Staphylococcus aureus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Kumar, A., Murray, D. L., Hanna, C. B., Kreindler, T. G., Jacobson, K. D., Bundy, J. M., ... Hill, C. D. (1988). Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections. Antimicrobial Agents and Chemotherapy, 32(6), 882-885. https://doi.org/10.1128/AAC.32.6.882

Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections. / Kumar, A.; Murray, D. L.; Hanna, C. B.; Kreindler, T. G.; Jacobson, K. D.; Bundy, J. M.; Waxman, K.; Finnerty, E. F.; Folan, D. W.; Drucker, W. R.; Kane, J. G.; Durnell, M.; DiMattia, A.; Hill, C. D.

In: Antimicrobial Agents and Chemotherapy, Vol. 32, No. 6, 01.01.1988, p. 882-885.

Research output: Contribution to journalArticle

Kumar, A, Murray, DL, Hanna, CB, Kreindler, TG, Jacobson, KD, Bundy, JM, Waxman, K, Finnerty, EF, Folan, DW, Drucker, WR, Kane, JG, Durnell, M, DiMattia, A & Hill, CD 1988, 'Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections', Antimicrobial Agents and Chemotherapy, vol. 32, no. 6, pp. 882-885. https://doi.org/10.1128/AAC.32.6.882
Kumar, A. ; Murray, D. L. ; Hanna, C. B. ; Kreindler, T. G. ; Jacobson, K. D. ; Bundy, J. M. ; Waxman, K. ; Finnerty, E. F. ; Folan, D. W. ; Drucker, W. R. ; Kane, J. G. ; Durnell, M. ; DiMattia, A. ; Hill, C. D. / Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections. In: Antimicrobial Agents and Chemotherapy. 1988 ; Vol. 32, No. 6. pp. 882-885.
@article{9f82749baf26468da534035f4b49f7f9,
title = "Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections",
abstract = "In two prospective, randomized multicenter double-blind studies with a dosage of either 250 mg given four times a day (study A) or 500 mg given two times a day (study B), the comparative efficacy and safety of cephalexin hydrochloride (LY061188; Keftab) and cephalexin monohydrate (Keflex) for treatment of skin and soft tissue infections were determined. In study A, 97 patients received cephalexin hydrochloride and 101 patients received cephalexin monohydrate. In study B, 75 patients received cephalexin hydrochloride and 70 patients received cephalexin monohydrate. Diagnoses included abscesses, cellulitis, would infections, and infected dermatitis, and were comparable in the different treatment groups. Pathogens were isolated from 82{\%} of patients enrolled; the majority of isolates were of Staphylococcus aureus, Streptococcus pyogenes, other staphylococcal species, and a few gram-negative bacteria. In study A, 68 of 71 (95.7{\%}) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 73 of 81 (90{\%}) patients who received cephalexin monohydrate also responded satisfactorily. In study B, 56 of 58 (96.5{\%}) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 47 of 50 (94{\%}) patients who received cephalexin monohydrate also responded satisfactorily. An adverse clinical event leading to discontinuation of the treatment drug developed in 17 of 343 (4.95{\%}) patients in both studies. No differences were noted between the two drugs. Skin eruptions, pruritis, and mild gastrointestinal symptoms were the common adverse effects. These data suggest that cephalexin hydrochloride, a new formulation of cephalexin, is a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in a dosage of either 250 mg four times a day or 500 mg twice a day.",
author = "A. Kumar and Murray, {D. L.} and Hanna, {C. B.} and Kreindler, {T. G.} and Jacobson, {K. D.} and Bundy, {J. M.} and K. Waxman and Finnerty, {E. F.} and Folan, {D. W.} and Drucker, {W. R.} and Kane, {J. G.} and M. Durnell and A. DiMattia and Hill, {C. D.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1128/AAC.32.6.882",
language = "English (US)",
volume = "32",
pages = "882--885",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Comparative study of cephalexin hydrochloride and cephalexin monohydrate in the treatment of skin and soft tissue infections

AU - Kumar, A.

AU - Murray, D. L.

AU - Hanna, C. B.

AU - Kreindler, T. G.

AU - Jacobson, K. D.

AU - Bundy, J. M.

AU - Waxman, K.

AU - Finnerty, E. F.

AU - Folan, D. W.

AU - Drucker, W. R.

AU - Kane, J. G.

AU - Durnell, M.

AU - DiMattia, A.

AU - Hill, C. D.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - In two prospective, randomized multicenter double-blind studies with a dosage of either 250 mg given four times a day (study A) or 500 mg given two times a day (study B), the comparative efficacy and safety of cephalexin hydrochloride (LY061188; Keftab) and cephalexin monohydrate (Keflex) for treatment of skin and soft tissue infections were determined. In study A, 97 patients received cephalexin hydrochloride and 101 patients received cephalexin monohydrate. In study B, 75 patients received cephalexin hydrochloride and 70 patients received cephalexin monohydrate. Diagnoses included abscesses, cellulitis, would infections, and infected dermatitis, and were comparable in the different treatment groups. Pathogens were isolated from 82% of patients enrolled; the majority of isolates were of Staphylococcus aureus, Streptococcus pyogenes, other staphylococcal species, and a few gram-negative bacteria. In study A, 68 of 71 (95.7%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 73 of 81 (90%) patients who received cephalexin monohydrate also responded satisfactorily. In study B, 56 of 58 (96.5%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 47 of 50 (94%) patients who received cephalexin monohydrate also responded satisfactorily. An adverse clinical event leading to discontinuation of the treatment drug developed in 17 of 343 (4.95%) patients in both studies. No differences were noted between the two drugs. Skin eruptions, pruritis, and mild gastrointestinal symptoms were the common adverse effects. These data suggest that cephalexin hydrochloride, a new formulation of cephalexin, is a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in a dosage of either 250 mg four times a day or 500 mg twice a day.

AB - In two prospective, randomized multicenter double-blind studies with a dosage of either 250 mg given four times a day (study A) or 500 mg given two times a day (study B), the comparative efficacy and safety of cephalexin hydrochloride (LY061188; Keftab) and cephalexin monohydrate (Keflex) for treatment of skin and soft tissue infections were determined. In study A, 97 patients received cephalexin hydrochloride and 101 patients received cephalexin monohydrate. In study B, 75 patients received cephalexin hydrochloride and 70 patients received cephalexin monohydrate. Diagnoses included abscesses, cellulitis, would infections, and infected dermatitis, and were comparable in the different treatment groups. Pathogens were isolated from 82% of patients enrolled; the majority of isolates were of Staphylococcus aureus, Streptococcus pyogenes, other staphylococcal species, and a few gram-negative bacteria. In study A, 68 of 71 (95.7%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 73 of 81 (90%) patients who received cephalexin monohydrate also responded satisfactorily. In study B, 56 of 58 (96.5%) evaluable patients who received cephalexin hydrochloride responded satisfactorily; 47 of 50 (94%) patients who received cephalexin monohydrate also responded satisfactorily. An adverse clinical event leading to discontinuation of the treatment drug developed in 17 of 343 (4.95%) patients in both studies. No differences were noted between the two drugs. Skin eruptions, pruritis, and mild gastrointestinal symptoms were the common adverse effects. These data suggest that cephalexin hydrochloride, a new formulation of cephalexin, is a safe and effective antimicrobial agent for treatment of a variety of skin and subcutaneous infections in a dosage of either 250 mg four times a day or 500 mg twice a day.

UR - http://www.scopus.com/inward/record.url?scp=0023940655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023940655&partnerID=8YFLogxK

U2 - 10.1128/AAC.32.6.882

DO - 10.1128/AAC.32.6.882

M3 - Article

C2 - 3046484

AN - SCOPUS:0023940655

VL - 32

SP - 882

EP - 885

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -